NCT03237052

Validating and Optimizing Model of Antipsychotics Selection

A Randomized Controlled Multi-center Clinical Study Focusing on Validating and Optimizing Model of Antipsychotics Selection in China

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 2,000 (estimated)
• Sponsor: Shanghai Mental Health Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This multi-centre study will evaluate the clinical efficacy of 3 atypical antipsychotics treatment in Chinese Patients with Schizophrenia by comparing model-decision with real-world psychiatrist-decision. The three atypical antipsychotics are olanzapine (5-20 milligram per day), risperidone (2-6 milligram per day) and aripiprazole (5-30 milligram per day). The main purpose of this study is to explore the potential difference between modal-aided-decision with clinician-decision in order to validate and optimize the selection model that has been established in advance. The efficacy evaluations include symptoms, social function, recurrence rate and hospitalization. Visits occurs at 0, 4, 8, 13, 26, 52 weeks.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
OTHER	model	a model that has been established in advance.
OTHER	non-model	real-world psychiatrist decision

Timeline

• Start date: 2018-01-01
• Primary completion: 2020-09-01
• Completion: 2020-12-01
• First posted: 2017-08-02
• Last updated: 2019-08-09

Locations

1 site across 1 country: China